Show simple item record

dc.contributor.authorReichmann, Heinz
dc.contributor.authorCooper, James
dc.contributor.authorRolfe, Katie
dc.contributor.authorMartínez-Martín, Pablo 
dc.date.accessioned2018-12-18T14:23:37Z
dc.date.available2018-12-18T14:23:37Z
dc.date.issued2011
dc.identifier.citationParkinsons Dis. 2011; 2011:354760es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6887
dc.description.abstractPatients undergoing long-term therapy for PD often experience motor fluctuations and nocturnal disturbances. In a post-hoc analysis, we explored effects of ropinirole prolonged release on sleep, night-time awakenings, and "on" time over 24 hours. Patients with advanced PD suboptimally controlled with L-dopa were randomized to adjunctive ropinirole prolonged release (2-24 mg/day) or placebo for 24 weeks. Awake/asleep and, if awake, "on"/"off" status was recorded via diary cards. At week 24 last observation carried forward, changes in nighttime or daytime sleep duration were not significantly different between treatments. Of patients with baseline awakenings, a significantly higher proportion in the ropinirole prolonged release group had a reduction in awakenings versus placebo. Patients receiving ropinirole prolonged release had a significantly greater increase in amount/percentage of awake time "on"/"on" without troublesome dyskinesia during all periods assessed (including night-time and early morning), versus placebo, and higher odds for being "on" on waking. Adjunctive once-daily ropinirole prolonged release may help provide 24-hour symptom control in patients with advanced PD not optimally controlled with L-dopa.es_ES
dc.description.sponsorshipThis study was supported by GlaxoSmithKline (GSK) R&D and SkyePharma.es_ES
dc.language.isoenges_ES
dc.publisherSAGE, Hindawi Access to Research es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleSleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Releasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución- 4.0 Internacional*
dc.identifier.pubmedID21687750es_ES
dc.format.volume2011es_ES
dc.format.page354760es_ES
dc.identifier.doi10.4061/2011/354760es_ES
dc.contributor.funderGlaxoSmithKline 
dc.contributor.funderSkyePharma 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2042-0080es_ES
dc.relation.publisherversionhttp://dx.doi.org/10.4061/2011/354760es_ES
dc.identifier.journalParkinson's diseasees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución- 4.0 Internacional
This item is licensed under a: Atribución- 4.0 Internacional